Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy.

J Ophthalmol · 2020 · PMC7031713 · PMID 32089871

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

A recent cost analysis revealed that although the cost differential between intravitreal ranibizumab and PRP may not be significant at the 2-year follow-up, over a lifetime this differential may increase significantly [ 29 ].

also in 2,774 other papers

highly significantno p-value reported

Duration of LTFU was a highly significant risk factor in determining the need for PPV.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.